The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

Elias Jabbour, Guillermo Garcia-Manero, A. Megan Cornelison, Jorge E. Cortes, Farhad Ravandi, Naval Daver, Tapan Kadia, Angela Teng, Hagop Kantarjian

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Myelosuppression in myelodysplastic syndromes (MDS) is associated with the hypomethylating agent decitabine. A retrospective pooled analysis of two decitabine clinical trials in patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modification, cycle delay or dose reduction, and survival effects. In 182 patients, baseline platelet dependence was a predictor for dose modification, reduction or delay, and death (modification: p = 0.006, hazard ratio [HR] = 2.04; reduction/delay: p = 0.011, HR = 2.00; death: p = 0.003, HR = 1.94). Patients with dose modifications had significantly higher overall response rates versus those with none (22% vs. 10%; p = 0.015). Patients with no dose modifications had faster progression to acute myeloid leukemia (AML) versus patients with dose modifications (p = 0.004). Without dose modifications, patients tended to drop out due to disease progression or other reasons. Decitabine dose modifications on treatment may indicate response to treatment.

Original languageEnglish (US)
Pages (from-to)390-394
Number of pages5
JournalLeukemia and Lymphoma
Volume56
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Keywords

  • Dacogen
  • Decitabine
  • Myelodysplastic syndromes
  • Retrospective study

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes'. Together they form a unique fingerprint.

  • Cite this

    Jabbour, E., Garcia-Manero, G., Cornelison, A. M., Cortes, J. E., Ravandi, F., Daver, N., Kadia, T., Teng, A., & Kantarjian, H. (2015). The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma, 56(2), 390-394. https://doi.org/10.3109/10428194.2014.914192